Thyroid papillary microcarcinoma
Conditions
Interventions
Active surveillance group:Patients observed with active surveillance, TSH suppression is given when it is necessary.
Microwave ablation group:Patients without TSH suppression after microwave ablation
Sponsors
Jiangsu Institute of Nuclear Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients volunteered to participate in the study and sign an informed consent form; 2. Age range from 18 to 70 years old (including 18 and 70 years old), ensuring that the expected follow-up period is greater than 5 years; 3. Fine needle aspiration cytological result is malignant or suspicious for malignancy (Bethesda V or VI), or histological diagnosis of core needle biopsy is papillary thyroid cancer; 4. The nodules with cytological result of Bethesda V should have highly suspicious features of ACR TIRADS; 5. The maximum diameter of the nodule is = 10mm; 6. The patients refuse surgical resection.
Exclusion criteria
Exclusion criteria: 1. Inability to understand or disagree with the research proposal; 2. Cytological diagnosis was aggressive variant PTC; 3. The tumor present with extrathyroidal extension; 4. The tumor adhered to the trachea at an obtuse angle and may be invaded; 5. Lymph node metastasis or distant metastasis was confirmed by imaging or cytology; 6. Clinical finding of trachea or recurrent laryngeal nerve invasion; 7. Underwent radiotherapy in the childhood; 8. Pregnancy; 9. Multiple suspicious lesions on imaging; 10. Contralateral vocal cord paralysis or dysfunction; 11. Patients with coagulation dysfunction and serious cardiopulmonary diseases who cannot tolerate treatment; 12. Subjects who are estimated to have insufficient compliance to participate in the clinical study or have other factors that the investigator considers unsuitable for participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Recurrence-free survival;Tumor recurrence rate;Local/distant tumor metastasis rate;Volume reduced rate at 1,3,6,12,24,36,48,60 months after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to Progression;Objective Response Rate;SF-36 and THYCA-QoL quality of life questionnaires; | — |
Countries
China
Contacts
Public ContactWu Hongxun
Jiangsu Institute of Nuclear Medicine
Outcome results
None listed